Luvo Health GLP-1 Review (2026): Pricing, Coverage, and Tradeoffs

Item: Luvo Health
Author: RangeYourself

Luvo Health review, semaglutide $194/mo on the 52-week plan for compounded injection (luvo's published $2,327 term total divided by 12 calendar months); $249 per 4-week term with no commitment. verified 2026-08-08., tirzepatide $291/mo on the 52-week plan for compounded injection (luvo's published $3,497 term total divided by 12 calendar months); $339 per 4-week term with no commitment. verified 2026-08-08.. Shoppers who want an openly published, no-intake-required price ladder for peptide/longevity therapy (sermorelin, NAD+) with named dispensing pharmacies. Independent 2026 review from RangeYourself.

By RangeYourselfLast verified 2026-08-08

Quick take

Luvo Health is compounded peptide and longevity therapies — sermorelin, and nad+ as injection, sublingual drops or nasal spray — alongside compounded glp-1, brand-name glp-1, hormone replacement, testosterone and dermatology lines., priced as cash-pay subscription billed per plan term of 4, 12, 24 or 52 weeks, with one openly published price per medication per term and no membership or separate consult fee; longer terms cost less per week. luvo's terms run in weeks, not calendar months, so every per-month figure shown here is its 52-week plan total divided by 12.. Best for: Shoppers who want an openly published, no-intake-required price ladder for peptide/longevity therapy (sermorelin, NAD+) with named dispensing pharmacies. Watch out for: Every ranked Luvo rate on this site is the 52-week (one-year) plan rate, expressed per calendar month — Luvo itself publishes plan-TERM totals in weeks, not monthly prices, and 52 weeks is 13 four-week cycles rather than 12. Buying without that year-long commitment costs materially more: the no-commitment 4-week term is $199 for sermorelin or NAD+ and $249 for compounded semaglutide. Luvo names four dispensing compounding pharmacies but states no 503A/503B status for any of them, makes no third-party testing or potency claim, and says its own evaluation does not include lab testing. Geographic availability is a qualified all-50-states claim: Luvo's Terms say some services may not be available in all states, and Luvo's affiliate program says a confirmed restricted-state list is still forthcoming from its clinical team.

Pricing summary

Price verified: 2026-08-08 (checked against the provider’s public pricing surface)
All-in monthly cost: $194/month (medication included), 52-week (annual) plan rate
Semaglutide: $194/mo on the 52-week plan for compounded injection (Luvo's published $2,327 term total divided by 12 calendar months); $249 per 4-week term with no commitment. Verified 2026-08-08.
Tirzepatide: $291/mo on the 52-week plan for compounded injection (Luvo's published $3,497 term total divided by 12 calendar months); $339 per 4-week term with no commitment. Verified 2026-08-08.
Compounded vs brand-name: Both compounded and brand-name
Insurance accepted: No insurance-billing path published (cash-pay); confirm at signup
Consult type: Async questionnaire, per the provider’s published flow
Dose-escalation pricing: Not published as a dose ladder. Luvo prices by medication and by plan term of 4, 12, 24 or 52 weeks, never by dose, and publishes the full term ladder for each medication on its own pricing page. Whether the price changes as the dose escalates is not stated anywhere on the public site — confirm at intake.
Refund policy: Published in full at /cancellation-and-refund-policy (last updated 2026-02-10). Full refund if a medical provider disqualifies you before medication is ordered. Cancel anytime, but requests must arrive at least 72 hours before the next billing date. Refunds only for the current billing cycle and only if medication has not yet been ordered; clinical services already rendered are non-refundable; federal law generally bars returning dispensed prescriptions. Bundled/multi-month plan refunds are prorated at the standard non-bundled retail price based on shipments already received.
States served: Luvo states it currently offers services in all 50 states plus Washington D.C., but its own Terms qualify that some services may not be available in every state — confirm your state and medication at signup

Check Luvo Health pricing →

Choose Luvo Health if

You want peptide/longevity pricing published openly on the website instead of gated behind an intake form
You want the dispensing pharmacy named before you buy (Luvo lists four in its Terms)
You are comparing sermorelin and the three NAD+ delivery forms at one provider
You are willing to commit to a longer term (24 or 52 weeks) to get the lowest per-week rate

Skip Luvo Health if

You want a price quoted per calendar month rather than per multi-week term, a published per-state or per-medication availability list, a stated 503A/503B pharmacy status, or third-party potency/purity testing evidence.

Contraindications and clinical notes

Luvo's FAQ states eligibility is clinician-determined and screens contraindications ('Some conditions, medications, pregnancy, or certain medical histories may make a treatment inappropriate'), and that services are adults-only. Per-product side-effect lists are published on each medication page. Standard GLP-1 contraindications apply to its GLP-1 lane.. Talk to a clinician about personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, or other conditions before starting any GLP-1 medication.

How Luvo Health compares

Frequently asked questions

How much does Luvo Health cost per month?

Luvo Health's lowest verified rate is $194/month with compounded medication included, and that figure is its 52-week (annual) plan rate rather than a month-to-month price. Semaglutide: $194/mo on the 52-week plan for compounded injection (Luvo's published $2,327 term total divided by 12 calendar months); $249 per 4-week term with no commitment. Verified 2026-08-08.; tirzepatide: $291/mo on the 52-week plan for compounded injection (Luvo's published $3,497 term total divided by 12 calendar months); $339 per 4-week term with no commitment. Verified 2026-08-08.. Not published as a dose ladder. Luvo prices by medication and by plan term of 4, 12, 24 or 52 weeks, never by dose, and publishes the full term ladder for each medication on its own pricing page. Whether the price changes as the dose escalates is not stated anywhere on the public site — confirm at intake.

Does Luvo Health accept insurance?

Luvo Health publishes cash-pay prices and we found no insurance-billing path on its own site. Where a provider's own FAQ leaves the door open, the answer sits inside its intake flow, which we do not enter, so confirm at signup rather than treating this as settled. If you want insurance-billed brand-name GLP-1, see our list of GLP-1 programs that accept insurance.

What states does Luvo Health serve?

Luvo states it currently offers services in all 50 states plus Washington D.C., but its own Terms qualify that some services may not be available in every state — confirm your state and medication at signup.

Is Luvo Health compounded or brand-name?

Luvo Health offers both compounded GLP-1 and brand-name GLP-1 depending on your eligibility and preference. On the brand side its own site lists: Ozempic® $1,299 and Zepbound® $1,399 per 4-week term, cash-pay — the only two brand-name products Luvo lists. Read from Luvo's own pricing page, www.luvohealth.com/pricing, on 2026-08-08. These are 4-week figures, not calendar-month figures, and no longer-term brand pricing is published: Luvo shows its brand products only on the 4-week tab. Luvo publishes no insurance-billing path against them.

What's the catch with Luvo Health?

Every ranked Luvo rate on this site is the 52-week (one-year) plan rate, expressed per calendar month — Luvo itself publishes plan-TERM totals in weeks, not monthly prices, and 52 weeks is 13 four-week cycles rather than 12. Buying without that year-long commitment costs materially more: the no-commitment 4-week term is $199 for sermorelin or NAD+ and $249 for compounded semaglutide. Luvo names four dispensing compounding pharmacies but states no 503A/503B status for any of them, makes no third-party testing or potency claim, and says its own evaluation does not include lab testing. Geographic availability is a qualified all-50-states claim: Luvo's Terms say some services may not be available in all states, and Luvo's affiliate program says a confirmed restricted-state list is still forthcoming from its clinical team. Avoid if: you want a price quoted per calendar month rather than per multi-week term, a published per-state or per-medication availability list, a stated 503a/503b pharmacy status, or third-party potency/purity testing evidence.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

About these products

These are compounded preparations, not FDA-approved for anti-aging or longevity indications, and a prescription from a licensed clinician is required. Compounding pharmacies are not individually reviewed by the FDA for the safety or effectiveness of a specific compounded product. We rank and describe these programs on price and access only, never on efficacy, outcomes, or benefit claims, and we do not repeat a provider’s own marketing claims as independently verified fact.

NAD+: NAD+ is not an FDA-approved drug, and its compounding status is not settled in its favor. In a warning letter to GenoGenix LLC dated January 20, 2026 (WL#718739), the FDA stated that NAD+ is not eligible for compounding by a 503B outsourcing facility. We could not identify a clear 503A pathway for it either: it has no USP monograph and is not a component of an approved drug. A Class I recall of an NAD+ injectable over endotoxin contamination is also on the record. We rank the programs on this page on published price only, and price is not a safety, quality, or eligibility signal here, confirm sourcing, the dispensing pharmacy, and any state restrictions directly with the provider before purchase, and discuss it with a prescribing clinician.

Sermorelin: not currently marketed as an FDA-approved product; it is compounded by licensed pharmacies for individual patients.

These peptide and longevity products are not identical to, and are never described here as generic or equivalent to, any FDA-approved drug, and unlike compounded GLP-1 medication most of them have no FDA-approved counterpart at all. State availability varies by provider and by product, several programs listed here disclose per-state restrictions; confirm eligibility in your state before purchase. RangeYourself does not provide medical advice and does not guarantee a prescription.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers verified on 2026-08-08 and may change.